Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis

Lisa A. Beck¹, Michael J. Cork², Masayuki Amagai³, Anna De Benedetto¹, Kenji Kabashima⁵, Jennifer D. Hamilton⁶ and Ana B. Rossi⁷

Skin barrier dysfunction, a defining feature of atopic dermatitis (AD), arises from multiple interacting systems. In AD, skin inflammation is caused by host–environment interactions involving keratinocytes as well as tissue-resident immune cells such as type 2 innate lymphoid cells, basophils, mast cells, and T helper type 2 cells, which produce type 2 cytokines, including IL-4, IL-5, IL-13, and IL-31. Type 2 inflammation broadly impacts the expression of genes relevant for barrier function, such as intracellular structural proteins, extracellular lipids, and junctional proteins, and enhances Staphylococcus aureus skin colonization. Systemic anti–type 2 inflammation therapies may improve dysfunctional skin barrier in AD.

INTRODUCTION

Atopic dermatitis (AD) is a chronic pruritic inflammatory skin disease, whose pathogenesis is mediated by interactions between skin barrier impairment and an abnormal immune response featuring enhanced type 2 inflammation (Figure 1). Interactions between keratinocytes (KCs), innate immune cells (e.g., type 2 innate lymphoid cells [ILC2s], dendritic cells, mast cells, basophils, and eosinophils), adaptive immune cells (T and B cells), and an altered epidermal microbiome (with reduction of microbial diversity and predominance of Staphylococcus aureus) all contribute to AD pathogenesis (De Benedetto et al., 2015; Dillon et al., 2004; Gittler et al., 2012; Gschwandtner et al., 2013; Jarrett et al., 2016; Kim et al., 2014; Kong et al., 2012; Mashiko et al., 2017; Onoue et al., 2009; Oyoshi et al., 2010; Sokol et al., 2008; Sonkoly et al., 2006).

Type 2 inflammation is characterized by overexpression of the cytokines IL-4, IL-5, IL-13, and IL-31 (Giustizieri et al., 2001; Gros et al., 2009; Hamid et al., 1996, 1994; Hardman et al., 2017; Kim et al., 2014; Leyva-Castillo et al., 2013; Mashiko et al., 2017; Neill et al., 2010; Oyoshi et al., 2010; Pivarsci et al., 2004; Schmitz et al., 2005; Sokol et al., 2008; Stott et al., 2013). These cytokines, particularly IL-4 and IL-13, act on both structural and immune cells (Figure 1). IL-4 and IL-13 signaling serves as a key initiating pathway for type 2 inflammatory diseases, whereas IL-4 amplifies the allergic inflammation observed in type 2 inflammatory diseases, including AD, asthma, allergic rhinitis, food allergy, and eosinophilic esophagitis (Davidson et al., 2019; Irvine and Mina-Osorio, 2019; Izuhara et al., 2002).

The functions of IL-4 and IL-13 overlap but are not identical (Figure 2). IL-4 and, to a lesser extent, IL-13 regulate class switching and IgE production by plasma cells (Gascan et al., 1991; Punnonen et al., 1993). IL-4 but not IL-13 promotes the differentiation of T helper (Th) cells from Th0 to Th2 cells (Gandhi et al., 2016; Paul, 2015; Swain et al., 1990). Both IL-4 and IL-13 induce different transcriptional changes in mast cells (McLeod et al., 2015; Nilsson and Nilsson, 1995) and are associated with fibrotic processes (Bhogal and Bona, 2008; Elbe-Bürger et al., 2002; Fichtner-Feigl et al., 2006; Gilly et al., 1992; Jessup et al., 2008; Kaviratne et al., 2004; Kolodskick et al., 2004; Oh et al., 2011; Oriente et al., 2000; Postlethwaite et al., 1992; Rankin et al., 2010; Zheng et al., 2009). They also activate Th0 cells, recruit inflammatory effector cells, downregulate the expression of FLG and other skin barrier proteins, and, at least in murine models, favor S. aureus colonization in inflamed skin (Bao and Reinhart, 2015; Cho et al., 2001a; Le Floc’h et al., 2020; Leyva-Castillo et al., 2020; Liang et al., 2011; Mitamura et al., 2012, 2018b; Swain et al., 1990). In addition, IL-4 and IL-13 directly act on sensory neurons, increasing their sensitivity to several pruritogens and contributing to the perpetuation of chronic itch in AD (Oetjen et al., 2017).

In this paper, we review the role of the components relevant to a functional skin barrier and highlight how skin barrier dysfunction promotes the development of type 2...
inflammation and how type 2 inflammation, in turn, affects skin barrier dysfunction.

THE SKIN BARRIER
The epidermis is the only epithelial surface with two barrier structures: the stratum corneum (SC), which is unique to the skin, and tight junctions (TJs), which are present in other epithelia as well (Elias, 1988; Kubo et al., 2009; Michaels et al., 1975; Yoshida et al., 2014, 2013). Both the SC and the TJs limit penetration of and reaction to microbes, allergens/irritants, and toxins as well as prevent trans-epidermal water loss (TEWL).

SC
Corneocytes. The SC, the outer layer of the epidermis, is composed of flattened, anucleated KCs (corneocytes) surrounded by a complex lipid-enriched extracellular matrix (Figure 3). Corneocytes are analogous to bricks and lipids to mortar in the original brick and mortar model of the SC (Elias, 1988; Michaels et al., 1975). This concept has since evolved
Keratins have multiple regulatory functions. For example, K1 downregulates the expression and secretion of the inflammatory cytokines IL-18, IL-33, and TSLP as well as damage-associated molecular patterns such as S100A8 and S100A9 (Roth et al., 2012). K16 downregulates the expression of damage-associated molecular patterns and other inflammatory molecules involved in the innate immune response to skin barrier disruption (Lessard et al., 2013).

Keratin expression is dysregulated in AD (Guttman-Yassky et al., 2019a). K16 expression is increased in suprabasal epidemis in AD, corresponding with abnormal KC proliferation (Guttman-Yassky et al., 2019a; Suárez-Fariñas et al., 2011). In contrast, K1 and K10 expression is downregulated by IL-4 and IL-13 in AD lesion skin versus in healthy controls, which might contribute to the SC barrier defects seen in patients with AD and the release of proinflammatory and type 2—promoting alarmins (Dai et al., 2021; Imai et al., 2013; Totsuka et al., 2017).
FLG is a key structural protein in KCs. Its precursor pro-FLG is expressed in the stratum granulosum (SG) layer and is the major component of keratohyalin granules (Presland et al., 1997; Resing et al., 1995). During terminal differentiation, pro-FLG is dephosphorylated and cleaved to generate multiple FLG monomers (Presland et al., 1997; Resing et al., 1995; Sandilands et al., 2009).

FLG has multiple functions. It binds to keratin filaments in the KC cytoskeleton, forming an FLG—keratohyalin complex that cross-links to the cornified envelope, transforming KCs into arguably impervious corneocytes (i.e., “bricks”) (Eckhart et al., 2013; Presland et al., 1997; Sandilands et al., 2009). FLG degradation by the protease caspase-14 in outer SC layers produces natural moisturizing factors (NMFs) (see below) (Hoste et al., 2011). FLG and NMFs are controlled in a finely balanced process of production, proteolysis, and inhibition that is crucial to skin barrier structure; hydration; and function, including pH regulation, microbial ecology, and possibly even UV protection (Barker et al., 2007; Denecker et al., 2007; Kawasaki et al., 2012; Palmer et al., 2006; Sandilands et al., 2007; Smith et al., 2006).

Reduced expression and loss-of-function mutations of FLG are common in AD (Barker et al., 2007; Baurecht et al., 2007; Nomura et al., 2008; Palmer et al., 2006; Weidinger et al., 2008, 2007). Prevalence and types of FLG loss-of-function mutations vary among populations, with a very wide variation being reported for patients with AD (Barker et al., 2007; Baurecht et al., 2007; Brown and McLean, 2012; Nomura et al., 2008; Palmer et al., 2006; Weidinger et al., 2008, 2007). FLG loss-of-function mutations are associated with more severe AD (Brown and McLean, 2012, 2009; Brown et al., 2008a; Margolis et al., 2012; Weidinger et al., 2007), earlier onset of AD, greater risk of allergen sensitization and other atopic disorders (Brown et al., 2011; Palmer et al., 2007), and higher incidence of eczema herpeticum (Gao et al., 2009). FLG loss-of-function mutations are also associated with mild AD, but the association is weaker than that seen for severe disease (Brown et al., 2008b).

Notably, FLG expression may be reduced in patients with AD without FLG mutations. Type 2 inflammatory mediators, including IL-4, IL-13, IL-31, IL-33, and TSLP, reduce FLG expression (Howell et al., 2009, 2007; Kim et al., 2015; Sehra et al., 2010; Selittmann et al., 2015). This has also been observed in skin inflammation mediated by Th17 (IL-17), Th22 (IL-22), and Th1 (IL-1α, IL-1β, and TNF-α) (Archer et al., 2019; Boniface et al., 2005; Danso et al., 2014; Gutowska-Owsiak et al., 2012, 2011; Kezic et al., 2012; Oyoshi et al., 2009; Tan et al., 2017). Repetitive scratching, detergent use, low humidity, exogenous or endogenous proteases, air pollution, and topical or oral corticosteroids can also reduce FLG expression (Danby et al., 2014; Goleva et al., 2019; Sheu et al., 1997, 1991; Thyssen and Kezic, 2014). FLG has multiple repeats (typically 10–12) within the locus (Brown et al., 2012). Copy number variants are associated with AD in some but not all populations. For example, in a cohort study in Ireland, reduced copy numbers were more frequent in patients with AD than in normal controls (Brown et al., 2012), whereas studies in other populations did not find any association between copy number variation and the risk of AD (Fernandez et al., 2017; Fulton et al., 2022).

FLG deficiency is associated with reductions in SC structure, hydration, antimicrobial function, and epithelial buffering capacity in AD and increases in skin pH, percutaneous absorption, and protease activity (Brauweiler et al., 2013; Flohr et al., 2010; Kawasaki et al., 2012; Kezic et al., 2008; Thyssen and Kezic, 2014; Vávrová et al., 2014). FLG-knockdown KCs have reduced levels of K10, T1 proteins (zona occludens [ZO]-1, claudin [CLDN]-1, and occludin), and human β-defensin (hBD)-2; and increased cysteine proteases, which can degrade T1 proteins (Hönzke et al., 2016; Wang et al., 2017). Reduction in FLG expression reduces the levels of FLG metabolites such as NMFs. This results in an increase in SC pH, which activates serine proteases (Elías et al., 2008; Goleva et al., 2019; Wang et al., 2017) and induces the expression of the proinflammatory cytokines, IL-1α, IL-1β, and TSLP (Hönzke et al., 2016; Kezic et al., 2012; Nylander-Lundqvist and Egelrud, 1997; Wood et al., 1996). Reduced FLG expression is also linked to increased levels of arachidonic acid and its metabolite 12-hydroxy-eicosatetraenoic acid in KCs, leading to increased inflammation and impairing late epidermal differentiation (Blunder et al., 2017).

The manifestations of FLG-deficient skin are much more dramatic when combined with the biological actions of IL-4 and IL-13. For example, in an in vitro study, IL-4 and IL-13 stimulation induced spongiosis and increased epidermal thickening, skin pH, and permeability in both normal and FLG-deficient skin equivalents (Hönzke et al., 2016). However, in FLG-deficient equivalents, IL-4 and IL-13 decreased the levels of skin barrier proteins (e.g., involucrin and loricrin), T1 proteins (e.g., occludin), and hBD-2 and increased basal layer proliferation rates and TSLP levels to a greater extent than in normal skin equivalents. This suggests that the combination of type 2 immunity and FLG deficiency may promote AD development more than either alone.

NMFs are composed of FLG degradation products (i.e., free amino acids, uracanic acid, and pyrrolidine carboxylic acid), urea, and lactate derived from sweat. Under normal conditions, the decrease in hydration from middle to outer SC layers promotes FLG detachment from the corneocyte envelope and degradation, forming NMFs (Rawlings and Matts, 2005; Sandilands et al., 2009).

NMFs retain moisture, contributing to barrier function by promoting epidermal hydration through osmotic gradients that allow the movement of water into the corneocytes (Björklund et al., 2014; Kezic et al., 2008). NMFs maintain and buffer the acidic pH of the SC, which may reduce colonization by pathogenic bacteria (Kezic et al., 2008; Kriens and Kermici, 2000; Mijaiovic et al., 2010). NMFs also promote epidermal maturation and desquamation (Kezic et al., 2011). Decreased SC NMF levels are associated with dry skin and skin diseases such as ichthyosis vulgaris and AD. IL-4 and IL-13 reduce FLG levels and sweat secretion, which thereby affect NMF composition and function (Howell et al., 2009, 2007; Sehra et al., 2010).

Loricrin and involucrin are key structural proteins of the cornified envelope that anchor keratin filaments, providing mechanical strength and flexibility to the corneocytes (Candi
et al., 1998; Roth et al., 2012; Steinert and Marekov, 1995). Both loricrin and involucrin are highly insoluble in late-stage KC differentiation, resulting from disulfide and transglutaminase cross-linking within the molecules and to other proteins in the cell envelope in corneocytes (Hohl et al., 1991; Rice and Green, 1979; Steinert and Marekov, 1995). Loricrin is more prominent toward the cytoplasmic surface of the envelope, whereas involucrin is localized proximate to the lipid portion of the envelope (Jarnik et al., 2002; Steinert and Marekov, 1995).

IL-4 and IL-13 downregulate loricrin and involucrin expression in KCs (Kim et al., 2011, 2008), which may account for the reduced levels observed in AD. TNF-α reduces loricrin and involucrin expression, which also explains their reduced levels in psoriasis (Kim et al., 2011, 2008). Interestingly, silencing FLG expression in normal human KCs reduced involucrin expression but upregulated the expression of loricrin and IL-2, IL-4, IL-5, and IL-13 (Dang et al., 2015).

Proteases have multiple roles in the SC, mediated by both their direct proteolytic activity and through protease-activated receptors (PARs) (Figure 3). They influence SC cohesion, degrade corneodesmosome proteins (desmogleins and desmocollins) during homeostatic desquamation, regulate lipid synthesis by degrading enzymes that process extracellular lipids, and reduce lipid secretion into the extracellular matrix by stimulating the type 2 plasminogen receptor (Borgoño et al., 2007; Brattsand and Egelrud, 1999; Caubet et al., 2004; Hachem et al., 2006, 2005; Sales et al., 2010; Watkinson, 1999).

Serine protease activity is increased in both lesional and nonlesional AD skin (Komatsu et al., 2007; Voegeli et al., 2009). Increased serine protease activity compromises barrier function by increasing the degradation of corneodesmosomes and extracellular lipid-processing enzymes, reducing ceramide production (a characteristic abnormality of AD) (Borgoño et al., 2007; Di Nardo et al., 1998; Hachem et al., 2005, 2003; Imokawa et al., 1991). Serine proteases and cysteine proteases activate the PAR2 receptor, which regulates the secretion of lamellar bodies and cornification (Demerjian et al., 2008; Hachem et al., 2006), and is linked to increased inflammation, itch, and epidermal barrier disruption (Briot et al., 2009; Wilson et al., 2013). Both endogenous and exogenous proteases (e.g., from allergens, such as cockroach and dust mites, or from bacteria, such as S. aureus alpha-toxin) activate PAR2 (Ebeling et al., 2007; Hachem et al., 2006; Jeong et al., 2008; Kato et al., 2009). PAR2 activation reduces the expression of TJ proteins (occludin, CLDN-1, and ZO-1) and impairs TJ function, as assessed by reduced transepithelial electrical resistance (owing to a diminished barrier to ions) and increased permeability to small proteins (Nadeau et al., 2018). Thus both allergens and cutaneous dysbiosis may promote skin barrier disruption in AD through PAR2-mediated mechanisms. Finally, PAR2 agonists also increase the expression of IL-4 and IL-13 by mast cells, whereas PAR2 inhibition blocks IL-4 and IL-13 expression, decreases skin thickening, and suppresses itching in AD models (Barr et al., 2019). Of interest, Netherton syndrome, a monogenic AD-like syndrome characterized by the loss of serine protease inhibition due to a mutation in SPINK5 (which codes for the protease inhibitor LEKTI), is associated with kallikrein 5-mediated PAR2 activation resulting in the production of the pro—type 2 cytokine TSLP by KCs (Briot et al., 2010).

Matrix metalloproteinases (MMPs), which affect tissue remodeling and inflammatory cell migration into the epidermis, may also play an important role in AD pathogenesis (Groneberg et al., 2005; Harper et al., 2010; Purwar et al., 2008). MMP activity was 10–24 times greater in saline wash samples from AD lesional skin than in healthy controls, which do not normally express MMPs (Harper et al., 2010). IL-13 induces MMP-9 expression in KCs, and expression of both MMP-9 and IL-13 is increased in acute AD lesions (Purwar et al., 2008). MMP-12, which induces inflammatory cell aggregation, is also upregulated in lesional and nonlesional AD skin (Brunner et al., 2017; Pavel et al., 2020; Zhu et al., 2019).

**SC lipid components.** Skin barrier lipids are localized in the extracellular matrix surrounding corneocytes and are secreted from lamellar bodies before cornification (Figure 3) (Elias et al., 1998; Menon et al., 1992). By weight, these lipids include approximately 47% ceramides, 24% cholesterol, 18% cholesterol esters, and 11% free fatty acids (FFAs) (Ohno et al., 2015; Rawlings and Mats, 2005; van Smeden and Bouwstra, 2016). The SC contains several types of ceramides, many of which have very long fatty acid chains and are highly hydrophobic (Berdyshev et al., 2018; Rawlings and Mats, 2005; van Smeden and Bouwstra, 2016).

Lipids form densely packed layers in the central portion of the SC, becoming less densely packed and more gel-like closer to the surface (Brancalion et al., 2001; Pilgrim et al., 1999). Alterations of this packing pattern, resulting from altered lipid composition and lipid-chain shortening, are thought to contribute significantly to skin barrier impairment in AD (Berdyshev et al., 2018; Pilgrim et al., 2001; van Smeden and Bouwstra, 2016; van Smeden et al., 2014). Fatty acid chains are lengthened by elongases (Ewald et al., 2015; van Smeden and Bouwstra, 2016). The expression of the elongases ELOVL1, ELOVL3, and ELOVL6 is reduced in lesional AD skin, resulting in shortened fatty acid chains and increased skin barrier permeability (Berdyshev et al., 2018; Danso et al., 2017). The higher proportion of short fatty acids correlates with changes in lipid organization and skin barrier function and is associated with AD severity (Janssens et al., 2012; Li et al., 2017; van Smeden et al., 2014). IL-4 and IL-13 inhibit KCs expression of ELOVL1, ELOVL3, and ELOVL6 (Berdyshev et al., 2018; Danso et al., 2017), and IL-4 inhibits ceramide synthesis (Hatano et al., 2005).

**Sweat.** Sweat is an important component of the skin barrier. Sweat forms a protective layer on the SC surface, contributing to thermoregulation, moisturizing the skin surface, and regulating water retention (Murota et al., 2015). In addition to water, electrolytes, lactate, basic nitrogenous compounds (e.g., urea, ammonia), amino acids, and proteins (Hiragun et al., 2017), sweat contains antimicrobial peptides (AMPs) (e.g., dermcidin and cathelicidin [see below]) and secretory IgA, which protect against infection (Imayama et al., 1994; Metze et al., 1991; Murakami et al., 2002). TJs
TLs

TLs connect epithelial cells in the SG (Figure 3) (Kubo et al., 2009; Yoshida et al., 2014, 2013). Unlike desmosomes, which are structural connectors between KCs, TLs play a more active role in skin barrier function. The continuous barrier formed by TLs limits the penetration of allergens, microbes, and irritants and regulates TEWL (De Benedetto et al., 2011b; Furuse et al., 2002; Kirschner et al., 2013; Rahn et al., 2017; Yoshida et al., 2013). In the SG, KCs flatten and form a tetrahexadakahedron shape (a 14-sided polygon with eight hexagonal and six rectangular sides). A model based on this shape showed that TJ connections can be maintained by three SG cells, ensuring that KCs never lose contact with adjacent KCs during differentiation as KCs move outward toward the SC (Yokouchi et al., 2016; Yoshida et al., 2013).

TLs contain intracellular and extracellular proteins that control the movement of water, ions, and solutions between KCs (Anderson and Van Itallie, 2009; Kubo et al., 2009; Yoshida et al., 2014, 2013). The transmembrane proteins found in TLs include occludin, CLDN family members, and junctional adhesion molecules (Brandner et al., 2002; Ebnet et al., 2004; Furuse et al., 2002, 1998, 1993; Kirschner et al., 2010; Liu et al., 2000; Morita et al., 1998; Wang et al., 2018). These transmembrane proteins connect to a cytoplasmic plaque complex, composed of ZO proteins (ZO-1, ZO-2, and ZO-3), cingulin, and other proteins (Brandner et al., 2002; Citi et al., 1988; Helfrich et al., 2007; Kirschner et al., 2013; Malminen et al., 2003; Morita et al., 1998; Pummi et al., 2001). CLDN-1 is critically important for skin barrier function, first appreciated with the CLDN-1-deficient mouse which succumbs during infancy as the consequence of extensive epidermal water loss (Furuse et al., 2002).

Reduced CLDN-1 and CLDN-3 levels in human AD skin are associated with epidermal barrier dysfunction (De Benedetto et al., 2011a; Yamaga et al., 2018). Reduced CLDN-3 levels are associated with increased sweat leakage in patients with AD (Yamaga et al., 2018). In an in vitro study, reduced CLDN-1 expression enhanced herpes simplex viral spreading, suggesting a mechanism for the susceptibility of patients with AD to eczema herpeticum (De Benedetto et al., 2011b). A number of other CLDNs, including CLDN-4, CLDN-8, and CLDN-23, have been shown to be reduced in AD skin lesions (De Benedetto et al., 2011a; Esaki et al., 2015).

TLs also serve a fence function, separating two biologically distinct layers of the epidermis, that is, the cornifying KCs in the upper layer of the SG and the SC, and the stratum spinosum (Figure 3). Although Langerhans cell dendrites do not usually translocate through TLs in healthy skin, with minor physical trauma, they do, leading to reorganization of the TLs to preserve barrier integrity (Figure 3) (Kubo et al., 2009). This compensatory response prevents TEWL and limits antigen transit. In contrast, in AD lesional skin, greater numbers of Langerhans cell dendrites penetrate TLs, increasing their access to environmental antigens present on the epidermal surface (Figure 3) (Yoshida et al., 2014). Of interest, key innate immune receptors are only expressed on the basilar side of the epidermis (below the TLs) (Kuo et al., 2013). This loss of fence function observed in AD skin likely plays a role in allergen polysensitization, a characteristic of most patients with AD.

Type 2 inflammation may weaken TJ barrier function in AD. For example, in FLG-knockdown skin equivalents, IL-4 and IL-13 decreased the expression of occludin (Hönzke et al., 2016). Furthermore, it is possible that the ratio of IL-4 to IL-17 may determine the TJ barrier function because IL-4 blocks the robust barrier-enhancing effects of IL-17A on KCs (Brewer et al., 2019). In vitro studies with human epidermal equivalents have shown that IL-4, IL-13, and IL-31 reduce CLDN-1 expression (Gruber et al., 2015).

THE INFLAMMATORY RESPONSE IN AD AND SKIN BARRIER DISRUPTION

A vicious circle: skin barrier disruption induces type 2 inflammation, and type 2 inflammation increases barrier disruption

Epidermal damage activates the innate immune response in a proinflammatory cascade (Figure 4). Skin barrier disruption permits access to external antigens by Langerhans cells and dermal dendritic cells, which present antigens to naive T cells and activate allergen-specific Th2 cells, leading to the release of the canonical type 2 cytokines, IL-4 and IL-13 (Dillon et al., 2004; Jarrett et al., 2016; Oyoshi et al., 2010; Sonkoly et al., 2006). In response to barrier disruption and exposure to S. aureus and allergens, KCs and innate immune cells release chemokines (e.g., CCL1, CCL2, CCL3, CCL4, CCL5, CCL11, CCL13, CCL17, CCL22, CCL26, and CCL27) that attract proinflammatory cells (Gros et al., 2009; Homey et al., 2006; Pivarcsi et al., 2004). Skin barrier disruption also stimulates KCs to release alarmins (i.e., proinflammatory type 2 immunity-promoting cytokines such as TSLP, IL-18, IL-25, and IL-33). In turn, the alarmins induce ILC2s, Th2 cells, and basophils to release type 2 cytokines (Giustizieri et al., 2001; Gros et al., 2009; Hardman et al., 2017; Kim et al., 2014; Leyva-Castillo et al., 2013; Mashiko et al., 2017; Neill et al., 2010; Oyoshi et al., 2010; Pivarcsi et al., 2004; Schmitz et al., 2005; Sokol et al., 2008; Stott et al., 2013; Terada et al., 2006; Yoshimoto et al., 1999; Zedan et al., 2015). In addition, alarmins induce ILC2s...
Type 2 inflammation and Skin Barrier in AD

Subclinical inflammation
Acute lesions
Chronic lesions

Figure 4. Skin barrier disruption and type 2 inflammation in AD. In acute AD, barrier defects in compromised skin lead to increased permeability and penetration of environmental factors (e.g., microbes, allergens) (1). Skin barrier defects and infiltration of immune cells lead to type 2–mediated production of inflammatory cytokines (e.g., IL-4, IL-13, IL-31) (2). In the epidemis, epithelial barriers predisposed to type 2–mediated disease are characterized by barrier disruption and greater numbers of Langerhans cells with dendrites penetrating through TJs (3). In chronic AD, type 2 inflammatory responses lead to epithelial remodeling and proliferation (e.g., FLG and other proteins, lipids, and AMPs) (4). The inflammatory cascade is further intensified by IL-4...
responsive to itch-inducing substances, such as IL-31 and histamine (Oetjen et al., 2017), and act synergistically to stimulate acute and chronic itch and scratching behavior in mouse models (Campion et al., 2019). In addition, PAR2 receptors induce pruritus; activate T cells; increase the release of inflammatory mediators, including IL-13, TNF-α, and TSLP; and reduce TJ integrity (Buhl et al., 2020; Henehan and De Benedetto, 2019).

Skin barrier disruption affects sensory nerve ending positioning and density in AD (Figure 3) (Takahashi et al., 2019). Neuron density and branching are greater in AD skin than in normal skin; these changes are seen to a greater extent in chronic than in acute AD (Guseva et al., 2020; Sugiura et al., 1997; Urashima and Mihara, 1998). In normal skin, sensory nerve endings do not penetrate TJs owing to a pruning process mediated by KCs at or near TJs, but in lesional AD skin and mouse models, sensory neuron fibers penetrate TJs in areas of epidermal disruption (Takahashi et al., 2019). This is another example of the loss of the TJ fence function in patients with AD.

**Type 2 inflammation and epidermal hyperplasia**

Type 2 inflammatory cytokines induce epidermal hyperplasia, a characteristic histologic feature of disease activity in chronic AD. Epidermal hyperplasia is evaluated by measuring epidermal thickness, Ki-67–positive cells, and S100A8/A9 and K16 expression (Esaki et al., 2016; Guttman-Yassky et al., 2019a; Hamilton et al., 2014; Ungar et al., 2017). IL-4 and IL-13 contribute to epidermal hyperplasia through disruptive effects on the skin barrier by suppressing lipid and structural protein production and KC differentiation (Gittler et al., 2012; Guttman-Yassky et al., 2019a; Hamilton et al., 2014; Howell et al., 2008, 2007; Kim et al., 2008). In a mouse model of acute AD, basophils were the primary source of IL-4 and IL-13 in the skin (Pellefigues et al., 2021). In this model, basophils and IL-4 induced epidermal hyperplasia and skin barrier dysfunction associated with increased numbers of K10-positive KCs and Ki-67/K14–positive KCs and increased FLG expression and KC differentiation (Pellefigues et al., 2021). IL-22, which is found in AD lesional and nonlesional skin, is also a key driver of epidermal proliferation (Eyerich et al., 2009; Lou et al., 2017; Orfali et al., 2018; Suárez-Fariñas et al., 2011). IL-4 and IL-13 also promote fibrosis, leading to dermal thickening and scarring with increased collagen production, particularly in chronic AD (Figure 4) (Bhogal and Bona, 2008; Elbe-Bürger et al., 2002; Fichtner-Feigl et al., 2006; Gillery et al., 1992; Jessup et al., 2008; Kaviratne et al., 2004; Kolodsick et al., 2004; Oh et al., 2011; Oriente et al., 2000; Poslethwaite et al., 1992; Rankin et al., 2010; Zheng et al., 2009). In addition, inhibition of Notch signaling, which regulates KC differentiation, is associated with epidermal hyperplasia and enhanced the expression of TSLP, IL-4, and IL-13 (Dumontier et al., 2010; Murthy et al., 2012). Histamine binding to histamine 4 receptors stimulates KC proliferation, which may also contribute to hyperplasia (Glatzer et al., 2013). The counterbalance between epidermal hyperplasia (or proliferation) and differentiation (e.g., SC and TJ formation) suggests that
anything that leads to greater KC proliferation could lead to barrier dysfunction (Guttmann-Yassky et al., 2009; Pellefigues et al., 2021; Sladek, 2012).

THE SKIN AS AN ANTIMICROBIAL BARRIER

The epidermal surface serves as an antimicrobial barrier through interactions between the skin surface microbiome and skin surface components, including AMPs, lipids, NMFs, pH, innate receptors, and resident antigen-presenting cells as well as T cells. On healthy skin, the microbiome includes diverse microorganisms that regulate local immune responses, control T-regulatory cell function, and inhibit pathologic microbes, thereby contributing to the antimicrobial barrier (Cogen et al., 2010; Grice et al., 2009; Lai et al., 2010; Naik et al., 2012; Sanford and Gallo, 2013). Its composition is affected by the integrity and function of epidermal barrier components, including long-chain unsaturated FFAs, AMPs, and NMFs (Baurecht et al., 2018; Bragg et al., 2005; Feuillie et al., 2018; Takigawa et al., 2005).

Commensal bacteria, such as S. hominis, are important for skin homeostasis and host defense against S. aureus (Cogen et al., 2010; Nakatsuji et al., 2017). They produce proteins with antimicrobial activity and induce KCs to produce AMPs, which limit S. aureus growth (Cogen et al., 2010; Lai et al., 2010; Nakatsuji et al., 2017).

Dysbiosis is a feature of AD, with reduced microbial diversity compared with normal skin, and characterized by a predominance of S. aureus (Fyhrquist et al., 2019; Hijikata et al., 1999; Kong et al., 2012; Ricci et al., 2003; Simpson et al., 2018; Totte et al., 2016). Analyses have shown that the skin surface of 55–90% of patients with AD is colonized with S. aureus, versus 3–20% of healthy controls (Fyhrquist et al., 2019; Hijikata et al., 1999; Masenga et al., 1990; Park et al., 2013; Pascolini et al., 2011; Ricci et al., 2003). Reduced microbial diversity in patients with S. aureus skin colonization may result from enhanced type 2 inflammation and alterations in skin barrier function (Kong et al., 2012; Simpson et al., 2018). Interestingly, one study showed that infants’ skin was colonized with S. aureus before their AD was diagnosed (Meylan et al., 2017). This suggests that dysbiosis may contribute to AD onset or amplification of disease activity (Kobayashi et al., 2015). Interestingly, patients with AD and S. aureus colonization have more severe disease, with greater type 2 deviation, allergen sensitization, and skin barrier dysfunction (Byrd et al., 2017; Fyhrquist et al., 2019; Kong et al., 2012; Simpson et al., 2018). S. aureus toxins can induce mast cell degranulation, leading to increased itch, inflammation, and KC death, which is made worse by coexposure with IL-4 and IL-13 (Brauweiler et al., 2014; Lin et al., 2003; Nakamura et al., 2013; Sonkoly et al., 2006). S. aureus–derived superantigens disrupt epithelial barrier function and enhance epithelial chemokine expression, which may promote greater leukocyte infiltration (Lin et al., 2003; Savinko et al., 2005; Schlievert et al., 2019). What remains unclear is what initiates the abnormalities commonly observed in patients with AD and the cause–effect relationships between dysbiosis, epidermal barrier defects, and type 2 inflammation.

AMPs inhibit the growth of microbial pathogens and support epidermal surface colonization by nonpathogenic commensal microbes (Cogen et al., 2010; Lai et al., 2010; Nakatsuji et al., 2017; Ong et al., 2002). AMPs are produced by KCs and sweat gland cells in response to colonization/infection, inflammation, or barrier disruption (Brauweiler et al., 2005; Lee et al., 2008; Murakami et al., 2002). The most commonly studied AMPs are the cathelicidin LL-37, and hBD-2 and hBD-3, which together inhibit the growth of S. aureus. These are typically increased with inflammation; however, IL-4 and IL-13 inhibit their production (Hönzke et al., 2016; Nomura et al., 2003; Ong et al., 2002). AMPs are also commonly produced by activation of innate immune receptors, such as toll-like receptors (TLRs), present on epithelial cells. TLR2 is important for responding to S. aureus but is downregulated in patients with AD (Kuo et al., 2013). AMPs have additional roles in skin barrier maintenance. For example, hBD-3 and TLR2 agonists have also been shown to increase the expression of CLDNs and other factors that regulate TJs (Kiatsurayanon et al., 2014; Kuo et al., 2013).

Extracellular matrix lipids (e.g., FFAs and sphingomyelin) contribute to the antimicrobial barrier by limiting bacterial growth, maintaining acidic pH, and activating AMPs (Baurecht et al., 2018; Bibel et al., 1992; Jiang et al., 2013; Miller et al., 1988; Nakatsuji et al., 2010; Takigawa et al., 2005). Permeability barrier impairment due to increased surface pH and reduced levels of long-chain FFAs and sphingosine also impairs epidermal antimicrobial function (Bibel et al., 1992; Hülupisch et al., 2020; Miller et al., 1988; Zainal et al., 2020).

There is tremendous cross-talk between type 2 inflammation, S. aureus colonization, and epidermal barrier dysfunction (Figure 4). For example, patients with severe AD frequently have S. aureus strains on their skin that produce enterotoxins, proteases, lipases, and superantigens that enhance B-cell Ig class switching to IgE, increase epidermal expression of type 2 inflammation–promoting alarmins and cytokines, and disrupt skin barrier function (Brauweiler et al., 2019, 2017, 2013; Fyhrquist et al., 2019; Gould et al., 2007; Leung et al., 1993; Nakatsuji et al., 2017, 2016; Williams et al., 2017). Even toxin-deficient S. aureus strains have been shown to disrupt TJs (Oehnemus et al., 2008), supporting the notion that S. aureus colonization may contribute to barrier impairment and type 2 polarization in AD.

In contrast, type 2 inflammation enhances the expression of S. aureus adhesins, such as fibrinogen and fibronectin (Cho et al., 2001a, 2001b). In parallel, type 2 cytokines, particularly IL-4 and IL-13, inhibit the production of AMPs and FFAs from epidermal cells in patients with AD and increase skin surface pH (Berdyshev et al., 2018; Danso et al., 2017; Hönzke et al., 2016; Nomura et al., 2003; Ong et al., 2002), further evidence that IL-4 and IL-13 enhance susceptibility to S. aureus colonization and thereby disturb barrier integrity.

THERAPEUTIC INTERVENTIONS TARGETING THE SKIN BARRIER

Many topical and systemic therapies have been evaluated for their ability to improve skin barrier function in patients with AD. Topical medications include topical corticosteroids (TCSs), topical calcineurin inhibitors (TCIs), phosphodiesterase-4 (PDE-4) inhibitors, and Jak inhibitors.
LA Beck et al.
Type 2 Inflammation and Skin Barrier in AD

(Jakis) (Eichenfield et al., 2014; Katoh et al., 2020; Singh et al., 2020; Wollenberg et al., 2018a).

Topical medications

Topical medications, including TCS, TCI, the PDE-4 inhibitor crisaborole, and the Jaki delgocitinib and ruxolitinib, have been shown to improve AD lesional severity in clinical trials (Amano et al., 2015; Bissonnette et al., 2019a; Dähnhardt-Pfeiffer et al., 2013; Danby et al., 2014; Jensen et al., 2013, 2012, 2009; Nakagawa et al., 2020, 2019; Papp et al., 2021).

Topical medications differ in their effects on skin barrier function and type 2 inflammation. The TCIs pimecrolimus and tacrolimus have been shown to improve AD skin barrier structure and function at levels similar to or exceeding those observed with TCS (Dähnhardt-Pfeiffer et al., 2013; Danby et al., 2014; Jensen et al., 2013, 2012, 2011, 2009; Xhuaflaire-Uhoda et al., 2007). In adults with mild-to-moderate AD, both TCS and pimecrolimus improved SC hydration; TEWL; epidermal differentiation; the levels of loricin, involucrin, K5, K10, and K14; and epidermal hyperproliferation markers (e.g., K16) (Jensen et al., 2013, 2012, 2011). In contrast, TCS downregulated the expression of inflammatory biomarkers, involucrin, AMPs, hBDs, and lipid metabolism enzymes, and disrupted SC barrier structure, including lamellar body extrusion and lipid bilayer formation. In contrast, TCS normalized these structures (Jensen et al., 2013, 2012, 2011). In similar studies, tacrolimus significantly improved multiple measures of skin barrier function and structure versus TCS in patients with quiescent (Danby et al., 2014) and/or moderate (Dähnhardt-Pfeiffer et al., 2013; Xhuaflaire-Uhoda et al., 2007) AD.

In an intrapatient randomized double-blinded trial in 40 adults with mild-to-moderate AD, the PDE-4 inhibitor crisaborole significantly improved lesional skin barrier function compared with vehicle, as assessed by TEWL and immunohistochemistry, and modulated inflammatory and skin barrier–related biomarkers, including CLDN-8 and K16, which correlated with improved barrier function and lesional scores (Bissonnette et al., 2019a; Paller et al., 2016).

The topical pan-Jaki delgocitinib targets Jak1, Jak2, Jak3, and tyrosine kinase (TYK) 2. In mouse models of AD, delgocitinib upregulated keratin and loricin expression that had been downregulated by IL-4 and IL-13, improved skin barrier function (as assessed by TEWL), and increased NMF levels in KC cultures (Amano et al., 2015). Delgocitinib showed no effect on CLDN-1 and CLDN-4 staining versus vehicle, whereas TCS significantly decreased CLDN staining and caused significant skin atrophy versus delgocitinib (Anagawa-Nakamura et al., 2020).

Systemic medications

Conventional systemic immunosuppressive agents, such as corticosteroids, cyclosporine A, methotrexate, mycophenolate mofetil, and azathioprine, broadly target inflammation, but their use as treatments for AD is limited by safety concerns and the need to monitor for toxicities (Eichenfield et al., 2017; Katoh et al., 2020; Wollenberg et al., 2018b). To date, there is limited evidence that these treatments improve the skin barrier.

An increased understanding of AD pathogenesis has led to the development of systemic treatments specifically targeting type 2 inflammatory pathways. Data on their effects on skin barrier structure and/or function are available for the oral Jakis guscinib and tofacitinib and the mAbs tralokinumab, fezakinumab, GBR830, and dupilumab.

Two studies evaluated the effects of Jaki on skin barrier. A randomized, placebo-controlled, double-blind phase 1b trial evaluated oral guscinib (Jak1/2, TYK2, and spleen TYK inhibitor) in patients with moderate-to-severe AD (Bissonnette et al., 2019b; Pavel et al., 2019). On the basis of transcriptomic and immunohistochemistry analyses, guscinib downregulated serum and skin biomarkers for type 1, type 2, Th22, and Th17 inflammatory pathways; reduced epidermal hyperplasia, K16 expression, and inflammatory cell infiltrates; increased FLG expression; and shifted the gene expression profile of lesional skin toward that of nonlesional skin (Bissonnette et al., 2019b; Pavel et al., 2019). In a three-dimensional in vitro skin model in which IL-4 and IL-13 were used to induce AD-like changes, tofacitinib prevented AD-like histologic changes, maintained FLG expression, decreased the phosphorylation of STAT 3 and 6, upregulated the expression of KC differentiation genes (including desmocollin 1, FLG, involucrin, loricin, and K1), and downregulated the expression of genes associated with AD-related immune responses (Clarysse et al., 2019).

Four mAbs have been evaluated for their effects on the skin barrier in patients with AD (fezakinumab, GBR 830, tralokinumab, and dupilumab); of these, fezakinumab and GBR 830 are currently investigational. In a randomized, placebo-controlled, double-blinded, phase 2a clinical trial in adults with moderate-to-severe AD, fezakinumab (a mAb directed against IL-22) administered as intravenous monotherapy improved lesional skin gene expression profiles and epidermal markers for inflammation and epidermal proliferation in patients with high levels of IL-22 skin expression at baseline but not in those with low baseline IL-22 levels (Brunner et al., 2019). In a randomized, double-blind, placebo-controlled trial in adults with moderate-to-severe AD, GBR 830 (an anti-OX40 mAb) administered intravenously significantly decreased OX40-positive T-cell and OX40 ligand+ dendritic cell counts and significantly improved measures of epidermal hyperplasia, including reductions in epidermal thickness, K16 mRNA expression, and Ki-67+ cell counts, compared with placebo (Guttmann-Yassky et al., 2019b).

Tralokinumab is a mAb directed against IL-13 that has been approved in Europe for the treatment of adults with moderate-to-severe AD who are candidates for systemic therapy (European Medicines Agency, 2021a). In a phase 3 trial in adults with moderate-to-severe AD, tralokinumab significantly reduced the levels of S. aureus colonization (on the basis of routine culture techniques) on lesional skin compared with placebo (Wollenberg et al., 2021).

Dupilumab, a fully human mAb that inhibits the signaling of both IL-4 and IL-13 by blocking their shared receptor component (IL-4Rα), is approved for AD, asthma, and chronic rhinosinusitis with nasal polyps, which are diseases driven by type 2 inflammation (European Medicines Agency; 2021b; Pharmaceuticals and Medical Devices Agency, 2021; Regeneron, 2021). Dupilumab significantly improved abnormalities in skin barrier gene expression and epidermal
proliferation in patients with AD (Beck et al., 2014; Guttman-Yassky et al., 2019a; Hamilton et al., 2014; Rohner et al., 2021). In biopsy data from adult patients with moderate-to-severe AD in two randomized, placebo-controlled, double-blinded phase 1 studies, dupilumab significantly reduced the expression of inflammatory biomarkers and epidermal proliferation biomarkers (e.g., K6b, K16, Ki-67); upregulated the expression of epidermal barrier structure and function markers (e.g., MATN4, CLDN8, ELN, CLDN11); and shifted AD-related gene expression in lesional skin toward that resembling nonlesional skin (Beck et al., 2014; Hamilton et al., 2014). Similarly, in a randomized, placebo-controlled, double-blinded phase 2 study in adult patients with moderate-to-severe AD, dupilumab significantly reduced the expression of genes important in type 2 inflammation (e.g., IL-13, IL-31), epidermal hyperplasia (e.g., Ki-67, K16), T cells, and dendritic cells; reduced Th17 and Th22 activity; and shifted the expression profile of the AD-related transcriptome of lesional skin toward that resembling nonlesional skin (Beck et al., 2014; Hamilton et al., 2014). In an open-label transcriptomic analysis of tape strips and biopsies in adult patients with moderate-to-severe AD, biomarkers associated with healthy skin barrier that were decreased at baseline (e.g., keratins, FLG, periplakin, and lipid metabolism markers) showed increased expression after 16 weeks of treatment with dupilumab. Improvement in several of these skin barrier markers was significantly correlated with improvement in clinical signs (Mikhaylov et al., 2021). Finally, transcriptomic data from a European registry study (TREATgermany [German National Clinical Registry for Patients With Moderate-to-Severe Atopic Dermatitis]) of adults with moderate-to-severe AD showed that dupilumab treatment for 12 weeks led to a stronger normalization of skin barrier-related genes than cyclosporin (Mohus et al., 2021). In contrast, cyclosporine resulted in stronger improvement in the expression of certain KC differentiation markers (e.g., K16, K6A, P13, and LCE3A) and some genes related to immune pathways (e.g., IL2RA, IL9R, CXCL3, CTLA4, OX40-R/OX40, S100A8, and S100A9).

**Figure 6. Histologic changes observed with dupilumab treatment.** Lesional skin samples taken from AD subjects before and 16 weeks after treatment with placebo or dupilumab (300 mg subcutaneously every 2 weeks) were stained with H&E. These two representative cases are notable for epidermal hyperplasia, spongiosis with elongated rete ridges, and a disordered basket-weave pattern to the SC layers in the placebo (baseline and 16 weeks) and dupilumab (baseline) images. After dupilumab treatment (16 weeks), the epidermis is no longer hyperplastic or spongiotic, rete ridges have normalized, and the SC is compact. In addition, these changes are seen in the context of reduced inflammatory perivascular infiltrates. Images were provided with permission from Guttman-Yassky et al. (2019a), courtesy of Emma Guttman-Yassky, Center for Excellence in Eczema, Department of Dermatology, Icahn School of Medicine at Mount Sinai (New York, NY). AD, atopic dermatitis; SC, stratum corneum.
and the Th17/IL-23 axis (e.g., IL-22, IL-23A/p19, IL-12B/p40, and P13/elafin).

CONCLUSIONS

Skin barrier function depends on multiple interacting systems that affect structural and functional components of the skin, including the SC and TJIs, type 2 inflammatory pathways, cellular and extracellular components of the epithelium, and interactions with the microbiome and other environmental factors. Skin barrier dysfunction in AD is driven by genetic predisposition, environmental factors, and inflammation. It has been postulated that the rise in allergic diseases (including AD) in industrialized countries may be due to substances present in modern urban environments that can damage epithelial barriers, such as detergents and their additives, emulsifiers in food, and various pollutants (Akdis, 2021). The type 2 inflammatory cytokines IL-4 and IL-13 play an important role in the disruption of skin barrier function, affecting multiple components of the skin barrier and at the same time being induced by barrier disruption (Figure 6). Targeting type 2 cytokines in AD has a broad range of beneficial effects on the components of the skin barrier, including lipids, proteins, skin pH, corneocyte structure, TJIs, sweat glands, and the microbiome, reinforcing the notion that AD is a systemic type 2 inflammatory disease. Further research is needed to confirm to what extent type 2-targeted therapies can improve skin barrier function and what role this barrier repair plays in the clinical improvement seen in AD.

ORCID

Lisa A. Beck: http://orcid.org/0000-0002-8452-667X
Michael J. Cork: http://orcid.org/0000-0003-4428-2428
Masayuki Amagai: http://orcid.org/0000-0003-3314-7052
Anna De Benedetto: http://orcid.org/0000-0001-6293-435X
Kenji Kabashima: http://orcid.org/0000-0002-0773-0554
Jennifer D. Hamilton: http://orcid.org/0000-0003-1236-5245
Ana B. Rossi: http://orcid.org/0000-0001-5345-678X

AUTHOR CONTRIBUTIONS

Conceptualization: LAB, MJc, MA, ADB, KK, JDH, ABR; Funding Acquisition: JDH, ABR; Visualization: LAB, MJc, MA, ADB, KK, JDH, ABR; Writing - Original Draft Preparation: LAB, MJc, MA, ADB, KK, JDH, ABR; Writing - Review and Editing: LAB, MJc, MA, ADB, KK, JDH, ABR

ACKNOWLEDGMENTS

The authors gratefully acknowledge Emma Guttman-Yassky at the Center for Excellence in Eczema, Department of Dermatology, Icahn School of Medicine at Mount Sinai (New York, NY) and Takaharu Okada at RIKEN IMS (Yokohama, Japan) for their contributions of images to this manuscript and Sivan Harel of Regeneron Pharmaceuticals, Inc. (Tarrytown, New York) and Yufang Lu, formerly of Regeneron Pharmaceuticals, Inc., for their feedback on this manuscript. This study is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Medical writing and editorial assistance were provided by Vicki Schwartz and Ekaterina Semenova of Excerpta Medica funded by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc., in accordance with the Good Publication Practice guideline, https://www.acppojournals.org/doi/10.7326/M15-0288.

CONFLICT OF INTEREST

LAB is a consultant for AbbVie, Allakos, AstraZeneca, BenevolentAI Bio, DermTech, Galderma, Incyte, Janssen, LEO Pharma, Lilly, Novartis, Pfizer, Principia Biopharma, Rapt Therapeutics, Regeneron Pharmaceuticals, Inc., Ribon Therapeutics, Sanofi Genzyme, Sanofi-Aventis, and Stealth Biotherapeutics; an investigator for AbbVie, AstraZeneca, Kiniksa, LEO Pharma, Pfizer, Regeneron Pharmaceuticals, Inc., and Sanofi; and a stock owner of Medtronic, 3M, Moderna, and Gilead. MJc is an investigator and/or consultant for AbbVie, Astellas, Atopic, Boots, Dermavant, Eli Lilly, Galapagos, Galderma, Harvey Water Softeners, Hyphens Pharma, Johnson & Johnson, KymbaL, LEO Pharma, L’Oréal, Menlo Therapeutics, Novartis, Oxagen, Perrigo (ACO Nordic), Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and UCB Pharma. MA has received consulting fees, honoraria, grant support, and/or lecturing fees from Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Sanofi, Torii Pharmaceutical, Pola Pharma, and Kyowa Kirin. ADB is an investigator and/or consultant for Allakos, Dermira, Kiniksa, Regeneron Pharmaceuticals, Inc., Pfizer, and Sanofi Genzyme. KK has received consulting fees, honoraria, grant support, and/or lecturing fees from Japan Tobacco, LEO Pharma, Maruho, Mitsubishi Tanabe, Ono Pharmaceutical, Procter & Gamble, Sanofi, Taiho, and Torii Pharmaceutical. JDH is an employee and shareholder of Regeneron Pharmaceuticals, Inc. and is an inventor in Regeneron patents. ABR is an employee and may hold stock and/or stock options in Sanofi Genzyme.

REFERENCES

Akaiwa M, Yu R, Umeshiba-Suyama R, Terada N, Suto H, Kogo T, et al. Localization of human interleukin 13 receptor in non-haematopoietic cells. Cytokine 2001;13:75–84.
Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol 2021;21:739–51.
Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, et al. The Janus kinase inhibitor JTE-025 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling. J Allergy Clin Immunol 2015;136:667–77.e7.
Amanaga-Nakamura A, Ryoke K, Yasui Y, Shoda T, Sugai S. Effects of delgocitinib ointment 0.5% on the normal mouse skin and epidermal tight junction proteins in comparison with topical corticosteroids. Toxicol Pathol 2020;48:1008–16.
Anderson JM, Van Itallie CM. Physiology and function of the tight junction. Cold Spring Harb Perspect Biol 2009;1:a002584.
Archer NK, Jo JH, Lee SK, Kim D, Smith B, Orntes RV, et al. Injury, dysbiosis, and filaggrin deficiency drive skin inflammation through keratinocyte IL-1ζ release. J Allergy Clin Immunol 2019;143:412–43.e6.
Bao K, Reinhardt RL. The differential expression of IL-4 and IL-13 and its impact on type-2 immunity. Cytokine 2015;75:25–37.
Barker JNWN, Palmer CN, Zhao Y, Liao H, Hull PR, Lee SP, et al. Null mutations in the filaggrin gene (FLG) determine major susceptibility to early-onset atopic dermatitis that persists into adulthood. J Invest Dermatol 2007;127:564–7.
Barr TP, Garzia C, Guha S, Fletcher EK, Nguyen N, Wieschhaus AJ, et al. PAR2 peptiducin-based suppression of inflammation and itch in atopic dermatitis models. J Invest Dermatol 2019;139:412–21.
Baurecht H, Irvine AD, Novak N, Illig T, Bühler B, Ring J, et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007;120:1346–12.
Baurecht H, Rühlemann MC, Rodríguez E, Thielking F, Harder J, Erens AS, et al. Epidermal lipid composition, barrier integrity, and eczematous inflammation are associated with skin microbiome configuration. J Allergy Clin Immunol 2018;141:1668–76.e16.
Beck LA, Thaci D, Hamilton JD, Graham NM, Bieber T, Rocklin R, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 2014;371:130–9.
Berdyshew E, Goleva E, Bronova I, Dyjack N, Rios C, Jung J, et al. Lipid abnormalities in atopic skin are driven by type 2 cytokines. JCI Insight 2018;3:e98006.
Bhogal RK, Bona CA. Regulatory effect of extracellular signal-regulated kinases (ERK) on type 1 collagen synthesis in human dermal fibroblasts stimulated by IL-4 and IL-13. Int Rev Immunol 2008;27:472–96.
Bibel DJ, Aly R, ShireineGHR. Antimicrobial activity of sphingosines. J Invest Dermatol 1992;98:269–73.
Bieber T. Targeting T2 inflammation by dupilumab impacts on the microbiome “ménage à trois” of atopic dermatitis. J Invest Dermatol 2020;140:13–7.
Bissonnette R, Maari C, Forman S, Bhatia N, Lee M, Fowler J, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASNO02 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study. Br J Dermatol 2019b;181:733–42.
Bissonnette R, Pavel AB, Diaz A, Rongioletti F, Paus R, et al. T cell infiltration and atopic dermatitis skin biomarkers: an intrapatient randomized trial. J Allergy Clin Immunol 2019a;144:1274–89.

Björklund S, Andersson JM, Pham QD, Nowacka A, Topgaard D, Sparre P. Stratum corneum molecular mobility in the presence of natural moisturizers. Soft Matter 2014;10:4335–46.

Blundel S, Rühl R, Moosbrugger-Martínez V, Kimmel C, Geisler A, Zhu H, et al. Alterations in epidermal eicosanoid metabolism contribute to inflammation and impaired late differentiation in FLG-mutated atopic dermatitis. J Investig Dermatol 2017;137:706–15.

Boniface K, Bernard FX, Garcia M, Guney AL, Jereb J, Morel F. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005;174:3695–702.

Borgoño CA, Michael IP, Komatsu N, Jayakumar A, Kapadia R, Clayman GL, et al. IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 2005;174:3695–702.

Brown SJ, Asai Y, Cordell HJ, Campbell LE, Zhao Y, Liao H, et al. Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. J Allergy Clin Immunol 2011;127:661–7.
Dai X, Utsunomiya R, Shiraishi K, Morii H, Muto J, Murakami M, et al. Nuclear IL-33 plays an important role in the suppression of FLG, LOR, keratin 1, and keratin 10 by IL-4 and IL-13 in human keratinocytes. J Invest Dermatol 2021;141:2646–55.e6.

Dansby SG, Chittock J, Brown K, Albenali LH, Cork MJ. The effect of tacrolimus compared with betamethasone valerate on the skin barrier in volunteers with querious atopic dermatitis. Br J Dermatol 2014;170:914–21.

Dang NN, Pang SG, Song HY, An LG, Ma XL. Filaggrin silencing by shRNA directly impairs the skin barrier function of normal human epidermal keratinocytes and then induces an immune response. Braz J Med Biol Res 2015;48:39–45.

Danoa M, Boiten W, van Drongelen V, Gmelig Meijling K, Gooris G, Elbe-Bürgel A, et al. Altered expression of epidermal lipid biosynthesis enzymes in atopic dermatitis skin is accompanied by changes in stratum corneum lipid composition. J Dermatol Sci 2017;80:57–66.

Danso MO, van Drongelen V, Mulder A, van Esch J, Scott H, van Smeden J, et al. TNF-α and Th2 cytokines induce atopic dermatitis-like features on epidermal differentiation proteins and stratum corneum lipids in human skin equivalents. J Invest Dermatol 2014;134:1941–50.

Davidson WF, Leung DYM, Beck LA, Berin CM, Boguniewicz M, Russe VW, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on “Atopic dermatitis and the atopic march: mechanisms and interventions.” J Allergy Clin Immunol 2019;143:894–913.

De Benedetto A, Raafas NM, McGregor IY, Ivanov AI, Georas SN, Cheadle E, et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011a;127:773–86.e1–7.

De Benedetto A, Slika MK, Raafas NM, Kuo IH, Georas SN, Boguniewicz M, et al. Reductions in claudin-1 may enhance susceptibility to herpes simplex virus 1 infections in atopic dermatitis [published correction appears in J Allergy Clin Immunol 2011b;128:903]. J Allergy Clin Immunol 2011b;128:242–6.e5.

De Benedetto A, Yoshida T, Friddy S, Park JE, Kuo IH, Beck LA. Histamine and skin barrier: are histamine antagonists useful for the prevention or treatment of atopic dermatitis? J Clin Med 2015;4:741–55.

Demerjian M, Hachem JP, Tschachler E, Denecker G, Declercq W, Vandenabeele P, et al. Acute modulations in permeability barrier function regulate epidermal cornification: role of caspase-14 and the pro tease-activated receptor type 2. Am J Pathol 2008;172:86–97.

Denecker G, Hoste E, Gilbert B, Hochepied T, Ovaere P, Lippens S, et al. Caspase-14 protects against epidermal UVB photodamage and water loss. Nat Cell Biol 2007;9:666–74.

Di Nardo A, Wertz P, Giannetti A, Seidenari S. Ceramide and cholesterol composition of the skin of patients with atopic dermatitis. Acta Derm Venereol 1998;78:27–30.

Dillon SR, Sprecher C, Hammond A, Billsborough J, Rosenfeld-Franklin M, Pressnell SR, et al. Interleukin-31, a cytokine produced by activated T cells, induces dermatitis in mice [published correction appears in Nat Immunol 2015a;16:905]. Nat Immunol 2005;6:752–60.

Dumortier A, Durham A-D, Di Piazza M, Vauclair S, Koch U, Ferrand G, et al. Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol 2015;141:1337–43.

Elbe-Bürger A, Egede A, Olt S, Klubal R, Mann U, Rappersberger K, et al. Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol 2002;118:767–76.

Elia PM. Structure and function of the stratum corneum permeability barrier. Drug Dev Res 1988;13:97–105.

Elia PM, Cullander C, Mauro T, Rassner U, Kömüves L, Brown BE, et al. The secretory granular cell: the outermost granular cell as a specialized secretory cell. J Invest Dermatol Symp Proc 1998;3:87–100.

Elia PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008;121:1337–43.

Esen H, Ewald DA, Ungar B, Rozenblit M, Zheng X, Zheng X, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol 2015;135:153–63.

Esen H, Brunner PM, Renert-Yuval Y, Czarnowicki T, Huyhn T, Tran G, et al. Early-onset pediatric atopic dermatitis is T12β but also T1717 polarized in skin. J Allergy Clin Immunol 2016;138:1639–51.

European Medicines Agency. Adtralza [EPAR: product information], https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf; 2012a. (accessed July 13, 2021).

European Medicines Agency. Dupixent (dupilumab) [EPAR: product Information], https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf; 2021b. (accessed July 1, 2021).

Eyerich S, Eyerich K, Pennino D, Carboni T, Nasorri F, Pallotta S, et al. Th22 community and remodeling. J Clin Invest 2009;119:3573–85.

Feld M, Garcia R, Buddenkotje J, Katayama S, Lewis K, Muirhead G, et al. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol 2016;138:500–8.e24.

Fernandez K, Asad A, Taylan F, Wahlgren CF, Bilcha KD, Nordenskjöld M, et al. Intragenic copy number variation in the filaggrin gene in Ethiopian patients with atopic dermatitis. Pediatr Dermatol 2017;34:140–1.

Feuille C, Vitry P, McAleer MA, Kezic S, Irvine AD, Georgiyan JA, et al. Adhesion of Staphylococcus aureus to corneocytes from atopic dermatitis patients is controlled by natural moisturizing factor levels. mBio 2018;9, e01184-18.

Fichtner-Feigl S, Strober W, Kawakami K, Puri RK, Kitani A. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nat Med 2006;12:99–106.

Finkelman FD, Katona IM, Urban JF, Holmes J, Ohara J, Tung AS, et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol 1988;141:3335–41.

Flioh C, Englund K, Radulovic S, McLean WH, Campbell LE, Barker J, et al. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. Br J Dermatol 2010;163:1333–6.

Fu DJ, Thomson C, Lunney DP, Dopping-Hepenstal PJ, McGrath JA, Smith FDJ, et al. Keratin 9 is required for the structural integrity and terminal differentiation of the palmarplantar epidermis. J Invest Dermatol 2014;134:754–63.

Fuchs E, Green H. Changes in keratin gene expression during terminal differentiation of the keratinocyte. Cell 1980;19:1033–42.

Fulton RL, Margolis DJ, Sockler PG, Mitra N, Wong XFCC, Common JE. No association of filaggrin copy number variation and atopic dermatitis risk in White and Black Americans. Exp Dermatol 2022;31:233–6.

Furuse M, Fujita K, Hiragi T, Fujimoto K, Tsukita S. Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 1998;141:1539–50.

Furuse M, Hata M, Furuse K, Yoshida Y, Horatake A, Sugiyama Y, et al. Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 2002;156:1099–111.

Furuse M, Hirase T, Itoh M, Nagauchi A, Yonemura S, Tsukita S, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993;123:1777–88.
patients with atopic dermatitis. J Allergy Clin Immunol 2019b;144:482–93.e7.

Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, Nogueiras KE, Shemer A, Fuentes-Duculan J, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 2009;124:1215–44.e58.

Hachem JP, Crumrine D, Fluh J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol 2003;121:345–53.

Hachem JP, Houben E, Crumrine D, Man MQ, Schurer N, Roelandt T, et al. Serine protease signaling of epidermal permeability barrier homeostasis. J Invest Dermatol 2006;126:2074–86.

Hachem JP, Man MQ, Crumrine D, Uchida Y, Brown BE, Rogiers V, et al. Sustained serine proteases activity by prolonged increase in pH leads to degradation of lipid processing enzymes and profound alterations of barrier function and stratum corneum integrity. J Invest Dermatol 2005;125:510–20.

Halim TFE, Rana BMJ, Walker JA, Kerscher B, Knolle MD, Jolin HE, et al. Tissue-restricted adaptive type 2 immunity is orchestrated by expression of the costimulatory molecule OX40L on group 2 innate lymphoid cells. Immunity 2018;48:1195–207.e6.

Hamid Q, Boguniewicz M, Leung DY. Differential in situ cytokine gene expression in acute versus chronic atopic dermatitis. J Clin Investig 1994;94:870–6.

Hamid Q, Naseer T, Minshall EM, Song YL, Boguniewicz M, Leung DY. In vivo expression of IL-12 and IL-13 in atopic dermatitis. J Allergy Clin Immunol 1996;98:225–31.

Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy 2021;51:915–31.

Hamilton JD, Suárez-Fariñas M, Dhingra N, Cardinale I, Li X, Kostic A, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014;134:1293–300.

Hardman CS, Chen YL, Salimi M, Jarrett R, Johnson D, Järvinen VJ, et al. CD1a presentation of endogenous antigens by group 2 innate lymphoid cells. Sci Immunol 2017;2:eaaan5918.

Harper JJ, Godwin H, Green A, Wilkes LE, Holden NJ, Moffatt M, et al. A study of matrix metalloproteinase expression and activity in atopic dermatitis using a novel skin wash sampling assay for functional biomarker analysis. Br J Dermatol 2010;162:397–403.

Hashimoto Y, Takaoka A, Sugimoto M, Homma Y, Sakurai T, Futaki N, et al. Itch-associated scratching contributes to the development of dermatitis and hyperimmunoglobulinemia E in NC/Nga mice. Exp Dermatol 2011;20:820–5.

Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol 2005;124:786–92.

Heilrich I, Schmitz A, Zigrino P, Michels C, Haase I, Le Bivic A, et al. Role of aPKC isoforms and their binding partners Par3 and Par6 in epidermal barrier formation. J Invest Dermatol 2007;127:782–91.

Henehan M, De Benedetto A. Update on protease-activated receptor 2 in cutaneous barrier, differentiation, tumorigenesis and pigmentation, and its role in related dermatologic diseases. Exp Dermatol 2019;28:877–85.

Higaki S, Morohashi M, Yamagishi T, Hasegawa Y. Comparative study of staphylococci from the skin of atopic dermatitis patients and from healthy subjects. Int J Dermatol 1999;38:263–9.

Hiragun T, Hiragun M, Ishii K, Kan T, Hide M. Sweat allergy: extrinsic or intrinsic? J Dermatol Sci 2017;81:1–9.

Hiragun T, Ishii K, Hiragun M, Suzuki H, Kan T, Mihrara S, et al. Fungal protein MGL_1304 in sweat is an allergen for atopic dermatitis patients. J Allergy Clin Immunol 2013;132:608–15.e4.

Hohl D, Mehrer T, Lichtl U, Turner ML, Roop DR, Steiner PM. Characterization of human loricrin. Structure and function of a new class of epidermal cell envelope proteins. J Biol Chem 1991;266:36–40.
Homberg M, Magin TM. Beyond expectations: novel insights into epidermal keratin function and regulation. Int Rev Cell Mol Biol 2014;311:265–306.

Homey B, Steinhoff M, Ruzicka T, Leung DYM. Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006;118:178–89.

Höncke S, Wallmeyer L, Ostrowski A, Radbruch M, Mundhenk L, Schäfer-Korting M, et al. Influence of Th2 cytokines on the cornified envelope, tight junction proteins, and β-defensins in filaggrin-deficient skin equivalents. J Invest Dermatol 2016;136:631–9.

Hoste E, Kemperman P, Devos M, Denecker L, Mundhenk L, Schäfer-Jarnik M, de Viragh PA, Schärer E, Bundman D, Simon MN, Roop DR, et al. Differential expression of epidermal antimicrobial protein expression in atopic dermatitis and in EFAD mice by pimecrolimus compared to corticosteroids. Exp Dermatol 2011;20:783–8.

Jensen JM, Pfeifer S, Witt M, Bräutigam M, Neumann C, Weihenthal M, et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J Allergy Clin Immunol 2009;124:1038 [published correction appears in J Allergy Clin Immunol 2009;123:1124–33].

Jensen JM, Scherer A, Wanke C, Bräutigam M, Bongiovanni S, Letzkus M, et al. Gene expression is differently affected by pimecrolimus and betamethasone in lesional skin of atopic dermatitis. Allergy 2012;67:413–23.

Jensen JM, Weppner M, Dähnhardt-Pfeiffer S, Neumann C, Bräutigam M, Schwarz T, et al. Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right–left arm trial. Acta Derm Venereol 2013;93:515–9.

Jeong SK, Kim HJ, Youn JK, Ahn SK, Choi EH, Sohn MH, et al. Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery. J Invest Dermatol 2008;128:1930–9.

Jessup HK, Brewer AW, Omori M, Rickel EA, Budelsky AL, Yoon BR, et al. Intradermal administration of thymic stromal lymphopoietin induces a T cell– and eosinophil-dependent systemic Th2 inflammatory response. J Immunol 2006;176:4311–9.

Jiang W, Sunkar RT, Zeng X, Dong Z, Myers SM, Zhang G. Differential regulation of human cathelicidin LL-37 by free fatty acids and their analogs. Peptides 2013;50:129–38.

Kato T, Takai T, Fujimura T, Tatsuka H, Ogawa T, Murayama K, et al. Mite serine protease activates protease-activated receptor-2 and induces cytokine release in human keratinocytes. Allergy 2009;64:1366–74.

Katoh N, Ohyà Y, Ikeda M, Ebihara T, Katayama I, Saeke H, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int 2020;69:356–69.

Kaviratne N, Hesse M, Leusink M, Cheever AW, Davies SJ, Mckerrow JH, et al. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004;173:4020–9.

Kawasaki H, Nagao K, Kubo A, Hata T, Shimizu A, Mizuno H, et al. Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice. J Allergy Clin Immunol 2012;129:4534–66.

Kezic S, Kemperman PMH, Koster ES, de Jongh CM, Thio HB, Campbell LE, et al. Loss-of-function mutations in the filaggrin gene lead to reduced skin barrier function and increased susceptibility to atopic eczema. Allergy 2012;67:412–8.

Kezic S, O’Regan GM, You N, Sandilands A, Chen H, Campbell LE, et al. Levels of filaggrin degradation products are influenced by both filaggrin genotype and atopic dermatitis severity. Allergy 2011;66:934–40.

Kezic S, O’Regan GM, Lutter R, Jakasa I, Koster ES, Saunders S, et al. Filaggrin loss-of-function mutations are associated with enhanced expression of IL-1 cytokines in the stratum corneum of patients with atopic dermatitis and in a murine model of filaggrin deficiency. J Allergy Clin Immunol 2012;129:1031–9.e1.

Kitsurayonon C, Niynsaba F, Smithrithee R, Akiyama T, Ushio H, Hara M, et al. Host defense (antimicrobial) peptide, human β-defensin-3, improves the function of the epithelial tight-junction barrier in human keratinocytes. J Investigative Dermatology 2014;134:2166–73.

Kim BE, Howell MD, Guttman-Yassky E, Gillelaudeau PM, Cardinale IR, Boguniewicz M, et al. TNF-z downregulates filaggrin and loricrin through c-Jun N-terminal kinase: role for TNF-z antagonists to improve skin barrier function. J Investigative Dermatology 2011;131:1388. [published correction appears in J Investigative Dermatology 2011;131:1388].

Kim BE, Leung DYM, Boguniewicz M, Howell LD. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol 2008;126:322–7.

Kim BS, Wang K, Siracusa MC, Saenz SA, Brestoff JR, Monticelli LA, et al. Basophils promote innate lymphoid cell responses in inflamed skin. J Immunol 2014;193:3717–25.

Kim JH, Bae HC, Ko NY, Lee SH, Jeong SH, Lee H, et al. Thymic stromal lymphopoietin downregulates filaggrin expression by signal transducer and activator of transcription 3 (STAT3) and extracellular signal-regulated kinase (ERK) phosphorylation in keratinocytes. J Allergy Clin Immunol 2015;136:205–8.e9.

Kirschnich N, Houdek P, Fromm M, Moll L, Brandner JM. Tight junctions form a barrier in human epidermis. Eur J Cell Biol 2010;89:839–42.

Kirschnich N, Rosenthal R, Furuse M, Moll L, Fromm M, Brandner JM. Contribution of tight junction proteins to ion, macromolecule, and water barrier in keratinocytes. J Invest Dermatol 2013;133:1161–9.
Kobayashi T, Glatz M, Horuchi K, Kawasaki H, Akiyama H, Kaplan DH, et al. Dysbiosis and Staphylococcus aureus colonization drives inflammation in atopic dermatitis. Immunity 2015;42:756–66.

Kolodzieck JE, Toews GB, Jakubczik C, Hogaboam C, Moore TA, McKenzie A, et al. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J Immunol 2004;172:4068–76.

Komatsu N, Saijoh K, Kuk C, Liu AC, Khan S, Shirasaki F, et al. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp Dermatol 2007;16:513–9.

Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antagonist, increases antimicrobial defense against bacterial skin infections. J Investig Dermatol 2013;133:988

Kubota A, Nagao K, Yokouchi M, Sasaki H, Amagai M. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. J Exp Med 2009;206:2937–40.

Kouklis PD, Hutton E, Fuchs E. Making a connection: direct binding between keratin intermediate filament and desmosomal proteins. J Cell Biol 1994;127:1049–60.

Krien PM, Kermici M. Evidence for the existence of a self-regulated enzymatic process within the human stratum corneum — an unexpected role for urocanic acid. J Investig Dermatol 2000;115:414–20.

Kubo A, Nagao K, Yokouchi M, Sasaki H, Amagai M. External antigen uptake by Langerhans cells with reorganization of epidermal tight junction barriers. J Exp Med 2009;206:2937–40.

Kumar V, Bouamour JE, Bär J, Rice RH, Hornig-Do HT, Roop DR, et al. A keratin scaffold regulates epidermal barrier formation, mitochondrial lipid composition, and activity [published correction appears in J Cell Biol 2016;212:877] J Cell Biol 2015;211:1057–75.

Kuo HJ, Carpenter-Mendini A, Yoshida T, McGirt LY, Ivanov AJ, Barnes KC, et al. Activation of epidermal toll-like receptor 2 enhances tight junction function: implications for atopic dermatitis and skin barrier repair. J Investig Dermatol 2013;133:988–98.

Lai Y, Cogen AL, Bouameur JE, Bär J, Rice RH, Hornig-Do HT, Roop DR, et al. A keratin scaffold regulates epidermal barrier formation, mitochondrial lipid composition, and activity [published correction appears in J Cell Biol 2016;212:877] J Cell Biol 2015;211:1057–75.

Lee CH, Coulombe PA. Self-organization of keratin intermediate filaments into cross-linked networks. J Cell Biol 2009;186:409–21.

Lee DY, Yamasaki K, Rudol J, Zouboulis CC, Park GT, Yang JM, et al. Seboocytes express functional cathelicidin antimicrobial peptides and can act to kill propionibacterium acnes. J Investig Dermatol 2008;128:1863–6.

Lessard JC, Pin˜a-Paz S, Rotty JD, Hickerson RP, Kaspar RL, Balmain A, et al. Skin colonization status in atopic dermatitis. Br J Dermatol 2017;177:e125–7.

Lin YT, Wang CT, Hsu CT, Wang LF, Shau WY, Yang YH, et al. Differential susceptibility to Staphylococcal superantigen (SsAg)-induced apoptosis of CD4+ T cells from atopic dermatitis patients and healthy subjects: the inhibitory effect of IL-4 on SsAg-induced apoptosis. J Immunol 2003;171:1102–8.
Murakami M, Ohkage T, Dorschner RA, Schittek B, Garbe C, Gallo RL. Cathelicidin anti-microbial peptide expression in sweat, an innate defense system for the skin. J Invest Dermatol 2002;119:1090–5.

Murata H, Matsu S, Ono E, Kijima A, Kikutaka J, Ishii M, et al. Sweat, the driving force behind normal skin: an emerging perspective on functional biology and regulatory mechanisms. J Dermatol Sci 2015;77:3–10.

Murata H, Yamaga K, Ono E, Katayama I. Sweat in the pathogenesis of atopic dermatitis. Allergol Int 2016;67:455–9.

Murthy A, Shao YW, Narala SR, Chun KA, Yan T, et al. Regulation of epidermal tight-junctions (TJ) during infection with exfoliative toxin-negative Staphylococcus strains. J Invest Dermatol 2008;128:906–16.

Ohno Y, Nakamichi S, Ohkuni A, Kamiyama N, Naoe A, Tsujimura H, et al. Essential role of the cytochrome P450 CYP4F22 in the production of acylceramide, the key lipid for skin permeability barrier formation. Proc Natl Acad Sci USA 2015;112:7707–12.

Ong PY, Ohkage T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:1151–60.

Onoue A, Kabashima K, Kobayashi M, Mori T, Tokura Y. Induction of eosi-nophil- and Th2-attracting epithelial chemokines and cutaneous late-phase reaction in tape-stripped skin. Exp Dermatol 2009;18:1036–43.

Orfali RL, da Silva Oliveira LM, de Lima JF, de Carvalho GC, Ramos YAL, Pereira NZ, et al. Staphylococcus aureus enterotoxins modulate IL-22-secreting cells in adults with atopic dermatitis. Sci Rep 2018;8:6665.

Oriente A, Fedarko NS, Paccofea SE, Huang SK, Lichtenstein LM, Essayam DM. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000;292:988–94.

Oyoshi MK, Larson RP, Ziegler SF, Geha RS. Mechanical injury polarizes skin dendritic cells to elicit a Th17-dominant skin inflammation and permissiveness to epicutaneous sensitization with protein antigen. J Allergy Clin Immunol 2009;124:485–493, 493.e1.

Paller AS, Tomas LC, Lebowohl MG, Blumenthal RL, Boguniewicz M, Call RS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults [published correction appears in J Am Acad Dermatol 2017;76:777.] J Am Acad Dermatol 2016;75:494–503.

Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006;38:441–6.

Palmer CN, Ismail T, Lee SP, Terron-Kwiatkowski A, Zhao Y, Liao H, et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007;120:64–8.

Papp K, Szepietowski JC, Kirilc K, Toth D, Eichenfeld LF, Leung DYM, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from phase 2, randomized, double-blind studies. J Am Acad Dermatol 2021;85:863–72.

Park HY, Kim CR, Huh IS, Jung MY, Seo EY, Park JH, et al. Staphylococcus aureus colonization in acute and chronic skin lesions of patients with atopic dermatitis. Ann Dermatol 2013;25:410–6.

Pascolini C, Sinagra J, Pecetta S, Bordignon V, De Santis A, Cilli L, et al. Molecular and immunological characterization of Staphylococcus aureus in pediatric atopic dermatitis: implications for prophylaxis and clinical management. Clin Dev Immunol 2011;2011:718708.

Paul WE. History of interleukin-4. Cytokine 2015;75:3–7.

Pavel AB, Song T, Kim HJ, Del Duca E, Krueger JG, Dubin C, et al. Oral Janus kinase/SYC inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in atopic dermatitis. J Allergy Clin Immunol 2019;144:1011–24.

Pavel AB, Zhou L, Diaz A, Ungar B, Dan J, He H, et al. The proteomic skin profile of moderate-to-severe atopic dermatitis patients shows an inflammatory signature. J Am Acad Dermatol 2020;82:690–9.

Pellegrues C, Naidoo K, Mehta P, Schmidt AJ, Jagot F, Roussel E, et al. Basophils promote barrier dysfunction and resolution in the atopic skin. J Allergy Clin Immunol 2021;148:799–812.e10.

Pharmaceuticals and Medical Devices Agency. Dupixent (dupilumab) [Japan PDMN], https://www.pmda.go.jp/PmdaSearch/IyakuDetail/GeneralList/4494005; 2021. (accessed September 1, 2021).

Pilgram GS, Vissers DC, van der Meulen H, Pavel S, Lavrijsen SP, Bouwstra JA, et al. aberrant lipid organization in stratum corneum of patients with atopic dermatitis and lamellar ichthyosis. J Invest Dermatol 2001;117:710–7.

Pilgram GSK, Engelsma-van Pelt AM, Bouwstra JA, Koerten HK. Electron deflection provides new information on human stratum corneum lipid
organization studied in relation to depth and temperature. J Invest Dermatol 1999;113:403–9.

Pivarcic A, Gombert M, Dieu-Nosjean MC, Lauerma A, Kubitza R, Meller S, et al. CC chemokine ligand 18, an atopic dermatitis-associated and dendritic cell-derived chemokine, is regulated by staphylococcal products and allergen exposure. J Immunol 2004;173:3810–7

Postlethwaite AE, Holness MA, Kati H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 1992;90:1479–85

Presland RB, Kimball JR, Kautsky MB, Lewis SP, Lo CY, Dale BA. Evidence for specific proteolytic cleavage of the N-terminal domain of human profilaggrin during epidermal differentiation. J Invest Dermatol 1997;108:170–8.

Pummi K, Malminen A, Aho H, Karvonen SL, Peltonen J, Peltonen S. Epidermal tight junctions: ZO-1 and occludin are expressed in mature, developing, and affected skin and in vitro differentiating keratinocytes. J Invest Dermatol 2001;117:1050–8.

Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, et al. Evidence of epithelial derived MMP-9 by IL-13: a possible role for the pathogenesis of atopic dermatitis. J Immunol 2010;184:3186–90.

Rankin AL, Murphey E, Turner S, Yu N, McClanahan TK, et al. IL-33 imparts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 2015;135:1659–61.e4.

Rankin K, Roth W, Kröger C, Loschke F, Lederer M, Hüttelmaier S, et al. Keratin mediate localization of hemidesmosomes and repress cell motility. J Investig Dermatol 2013;133:181–90.

Sheu HM, Lee JY, Yao HW, Leung DYM, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol 2010;184:3186–90.

Seltmann J, Roesner LM, von Hesler FW, Witting MT, Werfel T. IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 2015;135:1659–61.e4.

Seltmann K, Roth W, Wohlenberg C, Reuter U, et al. Keratin mediate localization of hemidesmosomes and repress cell motility. J Investig Dermatol 2013;133:181–90.

Shrimoda Komatsu Y, Sato Y, Yamazaki Y, Takahashi R, Shiohara T, A novel method to assess the potential role of sweating abnormalities in the pathogenesis of atopic dermatitis. Exp Dermatol 2018;27:386–92.

Suh J, Toi D, Hayakawa J. Defective sweating responses in atopic dermatitis. Curr Probl Dermatol 2011;41:68–79.

Simpson EL, Villareal M, Jeppson B, Dahlen S, Nijveldt RJ, et al. Patients with atopic dermatitis colonized with Staphylococcus aureus have a distinct phenotype and endotype. J Investig Dermatol 2018;138:2224–33.

Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis. Immunotherapy 2020;12:681–94.

Sokol CL, Barton GM, Farr AG, Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Rev Immunol 2008;8:310–8.

Sonkoly E, Muller A, Pavlics A, Sato H, Miyazaki Y, et al. IL-31: a new interleukin that induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc Natl Acad Sci USA 1993;90:3730–4.

Shimoda Komatsu Y, Sato Y, Yamazaki Y, Takahashi R, Shiohara T. A novel method to assess the potential role of sweating abnormalities in the pathogenesis of atopic dermatitis. Exp Dermatol 2018;27:386–92.

Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR. Emerging role of Janus kinase inhibitors for the treatment of atopic dermatitis. Immunotherapy 2020;12:681–94.
